3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
6
Other hematologic neoplasm
4
Gynecologic
3
Thoracic
2
Tumor-Agnostic
1
Sarcoma
1
Other solid neoplasm
1
Myeloid
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Interventions
Ipilimumab
101
pembrolizumab
94
Nivolumab
87
Cyclophosphamide
69
fludarabine phosphate
55
aldesleukin
52
Interleukin-2
39
Dacarbazine
35
Vemurafenib
31
fludarabine
30
trametinib
29
dabrafenib
29
Temozolomide
28
Whole-Body Irradiation
21
Aminolevulinic Acid
21
Carboplatin
20
CTLA-4 Antigen
20
Bevacizumab
20
Radiotherapy
19
Peripheral Blood Stem Cell Transplantation
19
Radiosurgery
18
Tacrolimus
17
Mycophenolic Acid
17
Paclitaxel
16
HhAntag691
16
3-ingenyl angelate
16
Busulfan
15
Introns
14
Antilymphocyte Serum
14
encorafenib
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
belinostat
×
Dermatologic
×
Clear all
NCT00274651
2015-07-28
PXD101-CLN-6
Valerio Therapeutics
Phase 2
Terminated
53 enrolled
12 charts